Welcome to our dedicated page for AMDOCS SEC filings (Ticker: DOX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amdocs Limited SEC filings document the disclosures of a foreign private issuer that provides software and services to communications and media companies. Its Form 6-K reports include quarterly and annual financial materials, consolidated financial statements, operating and financial review, earnings presentations, and disclosures on equity activity and issuer purchases.
The filing record also covers shareholder meeting materials and voting results, including board elections, employee share purchase plan amendments, dividend program approvals, auditor ratification, and governance changes involving executive leadership and board composition. Registration-statement incorporation language connects selected Form 6-K reports to Amdocs' equity compensation filings on Form S-8.
AMDOCS LTD (DOX) reported modest top-line growth but weaker profitability for the nine months ended June 30, 2026. Revenue rose to $3,502.8 million, up 3.6% year over year, with contributions from all regions and recent acquisitions; North America represented 64.7% of revenue, Europe 16.2% and the rest of the world 19.1%. Managed services remained a core engine, generating about $2.30 billion over nine months.
Operating income declined to $494.1 million from $599.0 million, and operating margin fell from 17.7% to 14.1%, mainly due to substantially higher restructuring charges of $128.1 million versus $6.8 million a year earlier. Net income attributable to Amdocs decreased 23.7% to $357.6 million, and diluted EPS declined to $3.33 from $4.17; excluding restructuring, diluted EPS would have been $4.40.
Cash generation remained strong, with $519.0 million of operating cash flow, while the company invested $217.6 million net in acquisitions (notably Matrixx Software) and repurchased $427.1 million of shares. Cash and cash equivalents were $206.5 million, supported by a revised $800 million revolving credit facility and a new commercial paper program, under which $200 million was outstanding. Twelve-month backlog stood at $4.26 billion, up 2.7% year over year, and remaining performance obligations were about $6.6 billion, most expected to convert to revenue within two years.
Amdocs Limited insider Tamar Rappaport Dagim filed to sell up to 33,584 ordinary shares through Oppenheimer & Co. Inc. on Nasdaq, with an aggregate value of $1,856,859.36. These shares were issued on 11/11/2023 upon vesting of RSUs for no cash consideration.
The filing also lists sales of 107,577 ordinary shares for $5,436,262.88 on 07/23/2026 and 12,780 ordinary shares for $702,902.56 on 07/28/2026 during the prior three months.
FMR LLC and Abigail P. Johnson report beneficial ownership of Amdocs Limited common stock. FMR LLC holds 10,032,312.93 shares, representing 9.4% of the class, with 8,783,014.17 shares having sole voting power and all 10,032,312.93 shares subject to sole dispositive power.
Abigail P. Johnson is reported as having sole dispositive power over the same 10,032,312.93 shares, also equal to 9.4% of the outstanding common stock. One or more other persons may receive dividends or sale proceeds from these shares, but no such person has an interest exceeding five percent of the total outstanding common stock.
Amdocs Limited reported Q3 fiscal 2026 revenue of $1.175 billion, up 2.7% year over year and in line with the midpoint of guidance, with managed services delivering a record quarter at 67% of revenue. Twelve‑month backlog reached $4.26 billion, up about 2.7% from a year earlier, supporting visibility.
GAAP net income was $63,193 (in thousands) and diluted EPS $0.59, down from $1.39 a year ago, mainly reflecting $106,424 (in thousands) of restructuring charges. Non‑GAAP net income rose to $195,940 (in thousands) and non‑GAAP EPS to $1.84, with non‑GAAP operating margin at 21.6%, up 20 basis points. Free cash flow was $171,924 (in thousands). Amdocs outlined a four‑pillar “agentic” growth strategy centered on its aOS Agentic Telco Operating System and announced a new 10‑year partnership with Liberty Latin America to transform and manage that customer’s entire IT domain. For fiscal 2026, it guides to revenue growth of 3.2%–4.0% as reported, non‑GAAP EPS growth of 5.5%–6.5%, GAAP EPS decline of 5.0%–3.0% versus prior 12.0%–15.0% growth guidance, and free cash flow of $710–$730 million.
Amdocs Ltd. reporting person Tamar Rapaport Dagim filed to potentially sell 12,780 Ordinary Shares of Amdocs Ltd. through Oppenheimer & Co. Inc., with an aggregate market value of $678,618.00, currently expected on July 28, 2026 on Nasdaq.
The shares were originally issued upon vesting of RSUs on November 11, 2023 for no cash consideration. The filing also notes that during the past three months, 107,577 Ordinary Shares were sold on July 23, 2026 for aggregate proceeds of $5,436,262.88.
Amdocs Limited has a notice of proposed sale under Rule 144 covering 107,577 ordinary shares, to be sold through Oppenheimer & Co. Inc. on Nasdaq, with an aggregate market value of $5,510,093.94. The filing states that these shares were originally issued upon vesting of restricted stock units (RSUs) on several dates between November 15, 2020 and November 5, 2024, in amounts ranging from 12,189 to 31,732 shares, for which no cash consideration was paid on vesting.
Pzena Investment Management, LLC has filed Amendment No. 2 to a Schedule 13G reporting beneficial ownership of 14,200,759 shares of Amdocs Ltd common stock, representing 13.2% of the class. Pzena, a Delaware limited liability company, is acting as investment manager for underlying clients.
The firm reports sole voting power over 10,893,470 shares and sole dispositive power over all 14,200,759 shares, with no shared voting or dispositive power. Clients of Pzena have the right to receive dividends and sale proceeds from these securities, and no single client’s interest relates to more than five percent of the class.
A Form 144 notice was filed reporting a proposed sale of 50,853 shares of ordinary stock by a selling person associated with Amdocs Ltd. The filing also lists recent issuances upon RSU vesting of 39,963, 35,368 and 39,786 ordinary shares. The filing shows 108,448,276 shares outstanding as of 06/22/2026.
Amdocs Ltd Chief Financial Officer Tal Rozenfeld has filed an initial ownership report showing holdings of 22,743 Ordinary Shares as of June 1, 2026. The reported amount includes Ordinary Shares that are subject to outstanding restricted stock awards, reflecting both vested and unvested equity-based compensation.
Amdocs Ltd executive Matthew E. Smith reported an open-market sale of company stock. On this Form 4, he sold 464 Ordinary Shares of Amdocs on May 29, 2026 at an average price of $62.51 per share, for roughly $29,000 in proceeds.
After the transaction, Smith directly holds 1,550 Ordinary Shares of Amdocs. The filing reflects a routine insider sale rather than a change in compensation or option exercise, and no derivative securities are reported as remaining positions.